Pharmaceutical company Lilly selects Virginia location for a $5 billion API manufacturing plant, focusing on Advanced Development and Chemistry processes (ADCS).
Eli Lilly to Build $5 Billion Manufacturing Plant in Goochland County, Virginia
Pharmaceutical giant Eli Lilly has announced plans to construct a new manufacturing facility in Goochland County, Virginia, as part of its $50 billion investment in expanding US manufacturing capacity since 2020. The new plant, estimated to cost $5 billion, will be the first-ever dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's bioconjugate platform and monoclonal antibody portfolio.
The facility, located in the West Creek Business Park, is expected to generate 1,800 construction jobs and more than 650 new high-paying jobs in engineering, science, operations, and lab technology. Once completed within five years, the plant will manufacture APIs for therapies designed to treat cancer, autoimmune diseases, and other disorders, including antibody-drug conjugates (ADCs).
Lilly chose Goochland County from "several hundred" applications due to factors such as the Greater Richmond workforce, utility and transportation access, zoning, and economic incentives. The Virginia Economic Development Partnership, Goochland County, and the General Assembly's Major Employment and Investment (MEI) Project Approval Commission worked together to secure the project for Virginia.
The new plant will mark a significant milestone for Lilly, as it represents the beginning of building its first bioconjugate facility. Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, expressed his excitement, stating, "This new facility is a testament to our commitment to U.S. innovation and manufacturing."
David A. Ricks, Lilly's chair and CEO, has stated that the investment will advance the health and well-being of Americans nationwide. Ricks has also credited President Donald Trump's earlier 2017 tax cuts with enticing Lilly to build its manufacturing sites in the United States.
The Virginia BioHealth Capital Region, which includes Maryland and Washington, D.C., ranks number three in GEN's Top 10 U.S. Biopharma Clusters. Lilly's decision to invest in Virginia follows AstraZeneca's announcement of a multi-billion-dollar manufacturing plant in the state, further solidifying Virginia's position as a hub for biopharmaceutical innovation.
Lilly plans to announce two manufacturing site announcements during the current third quarter, with the Virginia site and a site yet to be announced. The company also aims to roughly double its spending on U.S.-based manufacturing since 2020, making this new plant one of four new facilities.
The new Lilly plant is expected to create high-quality jobs and strengthen communities, further bolstering Virginia's economy and solidifying its position as a leader in the biopharmaceutical industry.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
.){kind=link}